Gender-Affirming Hormone Treatment Does Not Negatively Affect Bone Health
Gender-affirming hormone treatment may lead to changes in bone turnover markers in transgender men and women, but overall does not have negative effects on bone health.
Bone Health
Osteopenia Rates in Early Middle Age Indicate Increased Osteoporosis Screening Needs
Osteopenia was found in more than 25% of both men and women, suggesting that more osteoporosis screening and prevention programs are needed in middle-age individuals.
Osteoporosis Linked to Lower Quality of Life Regardless of Fracture History
Even without a history of fragility fracture, the presence of osteoporosis is associated with substantially lower health-related quality of life.
Parity, Lactation, and Fracture Risk: What’s the Link?
Parity and lactation had a neutral effect on the risk for fragility fractures or radiographic vertebral compression fractures over 10 years of follow-up.
FRAX Risk Tool Useful for Women Receiving Aromatase Inhibitor Therapy
The FRAX fracture risk tool can stratify fracture risk equally well among women receiving aromatase inhibitor (AI) therapy for breast cancer and nonusers of AI therapy.
Oral Bisphosphonates Linked to 6-Fold Increase in Risk for Osteonecrosis of the Jaw
The use of oral bisphosphonates is associated with a 6-fold increased risk for hospital admission with osteonecrosis of the jaw in postmenopausal women.
Research Needed to Improve Osteoporotic Drug Therapy: Takeaways From NIH Pathways to Prevention Workshop
Experts at the NIH’s Pathways to Prevention Workshop identified areas of research needed to advance long-term osteoporotic drug therapy.
Most Osteoporosis Guidelines Do Not Discuss Patient Beliefs, Preferences
Less than 40 percent of osteoporosis clinical practice guidelines include any mention of patients’ beliefs, values, or preferences.
Treatments for Preventing Fracture in Postmenopausal Women Compared
Overall, treatments that were associated with the greatest relative risk reduction in fragility fractures included teriparatide, abaloparatide, denosumab, romosozumab and most bisphosphonate.
Greater Improvements in Genetic Rickets With Burosumab vs Conventional Therapy
Burosumab was found to be superior to conventional therapy of oral phosphate and active vitamin D in children with X-linked hypophosphatemia.
Next post in ENDO 2019
